Abstract：
Most published guidelines for genomic biomarker testing in NSCLC reflect the disease epidemiology and treatments readily available in Europe and North America. Nevertheless, 60% of annual global NSCLC cases occur in Asia, where patient characteristics, tumor molecular profiles, and treatments vary greatly from the Western world. For example, mutations in the EGFR occur at a higher prevalence in Asia than in other world regions. Although medical associations such as the International Association for the Study of Lung Cancer, European Society for Medical Oncology, and American Society of Clinical Oncology have described principles for tumor genomic biomarker testing in NSCLC, there is a need for recommendations specific for Asia.
This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed.
These recommendations are divided into nonmetastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma. Owing to the higher prevalence of EGFR mutations in Asia, the experts emphasized the need for EGFR testing to include not just common mutations (exon 19 deletions and L858R substitutions) but also other uncommon EGFR mutations. In addition to the assessment of biomarkers in the tumor tissue, the role of assessing tumor biomarkers by liquid biopsy is discussed.
This consensus provides practical recommendations for biomarker testing in nonmetastatic and metastatic Asian NSCLC patients.
This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed.
These recommendations are divided into nonmetastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma. Owing to the higher prevalence of EGFR mutations in Asia, the experts emphasized the need for EGFR testing to include not just common mutations (exon 19 deletions and L858R substitutions) but also other uncommon EGFR mutations. In addition to the assessment of biomarkers in the tumor tissue, the role of assessing tumor biomarkers by liquid biopsy is discussed.
This consensus provides practical recommendations for biomarker testing in nonmetastatic and metastatic Asian NSCLC patients.
摘要：
背景：大多数发表的NSCLC基因组生物标志物检测指南反映了在欧洲和北美容易获得的疾病流行病学和治疗方法。然而，全球每年60%的非小细胞肺癌病例发生在亚洲，患者特征，肿瘤分子谱，治疗方法与西方世界差异很大。例如,EGFR突变在亚洲的患病率高于世界其他地区.尽管国际肺癌研究协会等医学协会，欧洲医学肿瘤学会，和美国临床肿瘤学会已经描述了NSCLC中肿瘤基因组生物标志物测试的原理，需要针对亚洲的具体建议。
方法：本报告为亚洲肺癌专家提供了NSCLC生物标志物检测的共识建议，供在亚洲工作的临床医生使用，以改善患者护理。EGFR可操作遗传改变的生物标志物测试方法，ALK,对ROS1等进行了讨论。
结果：这些建议分为非转移性和转移性腺癌和鳞状细胞癌。由于EGFR突变在亚洲的患病率较高，专家们强调,EGFR检测不仅需要包括常见突变(外显子19缺失和L858R取代),还需要包括其他不常见的EGFR突变.除了评估肿瘤组织中的生物标志物，讨论了通过液体活检评估肿瘤生物标志物的作用。
结论：这一共识为非转移性和转移性亚洲非小细胞肺癌患者的生物标志物检测提供了切实可行的建议。
方法：本报告为亚洲肺癌专家提供了NSCLC生物标志物检测的共识建议，供在亚洲工作的临床医生使用，以改善患者护理。EGFR可操作遗传改变的生物标志物测试方法，ALK,对ROS1等进行了讨论。
结果：这些建议分为非转移性和转移性腺癌和鳞状细胞癌。由于EGFR突变在亚洲的患病率较高，专家们强调,EGFR检测不仅需要包括常见突变(外显子19缺失和L858R取代),还需要包括其他不常见的EGFR突变.除了评估肿瘤组织中的生物标志物，讨论了通过液体活检评估肿瘤生物标志物的作用。
结论：这一共识为非转移性和转移性亚洲非小细胞肺癌患者的生物标志物检测提供了切实可行的建议。
